Drugs / ATGC-100
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03970876 | Apr → Sep 2019 | — | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04830345 | Jun 2020 → Sep 2021 | — | EuBiologics Co.,Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATGC-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04830345 ↗ |
| Route | Other | “ATGC-100 will be injected” NCT04830345 ↗ |